EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients

Alireza Abbaspour, Mehdi Dehghani, Mahtab Setayesh, Marjan Tavakkoli, Hossein Ali Rostamipour, Marziyeh Ghorbani, Mani Ramzi, Shapour Omidvari, Fatemeh Moosavi, Omidreza Firuzi iD

Cancer Chemotherapy and Pharmacology · 2023

DOI: 10.1007/s00280-023-04579-8 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Alireza Abbaspour und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Neoplasms, Anemia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Vice-Chancellor for Research, Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Gemcitabine is a chemotherapeutic agent, widely used for the treatment of many types of cancer. Cytidine deaminase (CDA) enzyme plays an important role in the metabolism of gemcitabine. This study aimed to assess the power of serum CDA residual activity in predicting drug efficacy and toxicity in gemcitabine-treated cancer patients. METHODS: This prospective observational study enrolled 63 patients with different types of malignancies who received gemcitabine chemotherapy between May 2019 and January 2022. Blood samples were obtained before the initiation of chemotherapy and serum CDA residual activity was determined using a modification of the Berthelot assay. The patients were followed up for at least 12 months up to 41 months. Overall survival was recorded and treatment-related toxicities were documented according to National Cancer Institute Common Terminology Criteria. RESULTS: Kaplan-Meier analysis showed that patients with a lower than median CDA value (≤ 8.06 U/mg protein) had a significantly longer survival compared to patients with higher CDA values (> 8.06 U/mg, P ˂ 0.005). Among several potentially involved factors, a significant association between CDA activity and overall survival was observed in univariate analysis (HR = 4.219, 95% CI 1.40-12.74, P = 0.011). On the other hand, the rate of anemia was significantly higher in low-CDA patients compared to high-CDA individuals (P < 0.05). CONCLUSION: These findings suggest that CDA activity could be a promising biomarker to predict survival and the occurrence of anemia in cancer patients treated with gemcitabine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAnemiaHumansGemcitabineDeoxycytidineBiomarkersCytidine Deaminase

Stichwörter der Autor:innen

BiomarkerCancer therapyNucleoside analoguesPancreatic cancerSolid tumors

Substanzen

GemcitabineDeoxycytidineBiomarkersCytidine Deaminase

Autor:innen und Institutionen

  • Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Internal Medicine, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Omidreza Firuzi

Förderung

  • Vice-Chancellor for Research, Shiraz University of Medical Sciences

Zitieren

APA

Abbaspour, A., Dehghani, M., Setayesh, M., Tavakkoli, M., Rostamipour, H. A., Ghorbani, M., Ramzi, M., Omidvari, S., Moosavi, F., & Firuzi, O. (2023). Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04579-8

Vancouver

Abbaspour A, Dehghani M, Setayesh M, Tavakkoli M, Rostamipour HA, Ghorbani M, et al. Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04579-8

BibTeX
@article{Abbaspour2023,
  author = {Abbaspour, Alireza and Dehghani, Mehdi and Setayesh, Mahtab and Tavakkoli, Marjan and Rostamipour, Hossein Ali and Ghorbani, Marziyeh and Ramzi, Mani and Omidvari, Shapour and Moosavi, Fatemeh and Firuzi, Omidreza},
  title = {Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  doi = {10.1007/s00280-023-04579-8}
}
Kostenlos starten →